NASDAQ · RCM
Healthcare · Medical - Healthcare Information Services
$14.31
Up+$0.00 (+0.00%)
Updated Aug 14, 2026, 10:56 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
RCM does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning RCM.
RCM research
Company profile and research snapshot.
R1 RCM Inc. provides technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. It offers end-to-end revenue cycle management (RCM) services, which address the spectrum of revenue cycle challenges faced by healthcare providers. The company also provides modular services, including physician advisory services, which assists healthcare organizations in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; revenue integrity solutions, including charge capture, charge description master maintenance, and pricing services; coding management services, such as business intelligence and analysis, human capital management, accountability framework, and quality management programs; patient experience; and business office services. In addition, the company offers software-as-a-service based scheduling and patient access solutions. The company was founded in 2003 and is headquartered in Murray, Utah.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 4, 2024 | Cantor Fitzgerald | Neutral | — |
| Aug 20, 2024 | Cantor Fitzgerald | Neutral | — |
| Aug 8, 2024 | Truist Securities | Hold | — |
| Aug 5, 2024 | TD Cowen | Hold | — |
| Aug 1, 2024 | Leerink Partners | Market Perform | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Aug 1, 2024
The law firm of Wohl & Fruchter LLP is investigating the fairness of the sale of R1 RCM to TowerBrook Capital Partners and Clayton, Dubilier & Rice for $14.30 per share, which is below the price targets set by Wall Street analysts.
Benzinga · Jul 22, 2024
The article provides an analysis of 8 analysts' insights on R1 RCM, a provider of technology-driven solutions for healthcare providers. The analysts have a mix of bullish and bearish perspectives, with an average 12-month price target of $17.38 and a range of $15.00 to $20.00.
GlobeNewswire Inc. · Jul 13, 2024
BFA Law is investigating the proposed acquisition of R1 RCM Inc. by New Mountain Capital for $13.25 per share, as the deal may not be fair to minority shareholders.
GlobeNewswire Inc. · Jul 6, 2024
BFA Law is investigating the proposed acquisition of R1 RCM Inc. by New Mountain Capital for $13.25 per share, as the deal may not be fair to minority shareholders.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RCM.
No results
No recent SID articles mention RCM.
